Corcept Therapeutics CORT Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $769.1M+1.0% | $761.41M+2.7% | $741.17M+3.5% | $716.08M+4.5% | $685.45M+1.5% | ||
| $13.46M+3.7% | $12.98M-3.1% | $13.39M+14.8% | $11.66M+8.5% | $10.75M-1.2% | ||
| $260.44M+2.2% | $254.91M-2.1% | $260.35M+3.8% | $250.84M+0.7% | $249.12M+0.9% | ||
| $503.42M+12.2% | $448.73M+11.7% | $401.86M+14.3% | $351.63M+11.7% | $314.71M+12.3% | ||
| $777.32M+8.5% | $716.61M+6.1% | $675.6M+10.0% | $614.13M+6.9% | $574.58M+6.8% | ||
| -$8.22M-118% | $44.8M-31.7% | $65.57M-35.7% | $101.95M-8.0% | $110.87M-19.0% | ||
| -1.1%-7.0pp | 5.9%-3.0pp | 8.8%-5.4pp | 14.2%-1.9pp | 16.2%-4.1pp | ||
| $20.35M-6.1% | $21.67M-5.6% | $22.94M-5.4% | $24.26M-3.9% | $25.25M+2.9% | ||
| $12.13M-81.7% | $66.46M-24.9% | $88.51M-29.9% | $126.21M-7.3% | $136.12M-15.7% | ||
| -$35.21M-6.1% | -$33.19M-88.6% | -$17.6M-136% | -$7.44M-451% | $2.12M-89.5% | ||
| $47.34M-52.5% | $99.65M-6.1% | $106.11M-20.6% | $133.66M-0.3% | $133.99M-5.1% | ||
| 6.2%-6.9pp | 13.1%-1.2pp | 14.3%-4.3pp | 18.7%-0.9pp | 19.5%-1.4pp | ||
| $0.35-57.3% | $0.82-5.7% | $0.87-22.3% | $1.12-2.6% | $1.15-6.5% | ||
| -$6.94M-115% | $45.95M-31.1% | $66.71M-35.3% | $103.12M-7.9% | $112.01M-18.7% | ||
| -0.9%-6.9pp | 6%-3.0pp | 9%-5.4pp | 14.4%-1.9pp | 16.3%-4.1pp | ||
| -$8.22M-118% | $44.8M-31.7% | $65.57M-35.7% | $101.95M-8.0% | $110.87M-19.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Corcept Therapeutics's revenue?
- Corcept Therapeutics (CORT) generated $769.1M in revenue over the trailing twelve months, up 12.2% year over year.
- Is Corcept Therapeutics profitable?
- Corcept Therapeutics reported $47.3M in net income over the trailing twelve months, a 6.2% net margin.
- What are Corcept Therapeutics's profit margins?
- Gross margin is 98.3% and operating margin is -1.1%, with a 6.2% net margin.
- What is Corcept Therapeutics's earnings per share?
- Corcept Therapeutics's diluted EPS over the trailing twelve months is $0.35.
- Where does Corcept Therapeutics's income statement data come from?
- Every line is extracted from Corcept Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
